Home LiteratureArticle Details
PMID: 18971951 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.

Leukemia ·Vol. 23 ·No. 1 ·2009-01-00 ·Pages 3-9

Kyle RA, Rajkumar SV

Abstract

New systems have emerged for diagnosis, staging and response assessment in multiple myeloma (MM). The diagnostic and response criteria recommended are primarily derived from the International Myeloma Working Group, with certain updates and clarifications. The International Staging System is the current standard for staging of myeloma. A new risk stratification model is provided to specifically define high-risk patients who may benefit from novel therapeutic strategies. This paper provides the current criteria for diagnosis, staging, risk stratification and response assessment of MM.

MeSH Terms
Diagnostic Techniques and Procedures Humans Multiple Myeloma/diagnosis Neoplasm Staging/standards Practice Guidelines as Topic Risk Assessment/standards Treatment Outcome
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Kyle R A
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. kyle.robert@mayo.edu
Rajkumar S V
References (29)
29 references, click to expand
  1. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
    Br J Haematol. 2003 Jun;121(5):749-57 PMID: 12780789
  2. Clinical and biologic implications of recurrent genomic aberrations in myeloma.
    Blood. 2003 Jun 1;101(11):4569-75 PMID: 12576322
  3. Genetics and cytogenetics of multiple myeloma: a workshop report.
    Cancer Res. 2004 Feb 15;64(4):1546-58 PMID: 14989251
  4. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.
    Cancer. 1975 Sep;36(3):842-54 PMID: 1182674
  5. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.
    Br J Haematol. 1983 Nov;55(3):439-47 PMID: 6357266
  6. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
    Blood. 1993 Jun 15;81(12):3382-7 PMID: 8507875
  7. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.
    Blood. 1995 Dec 1;86(11):4250-6 PMID: 7492784
  8. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
    Br J Haematol. 1998 Sep;102(5):1115-23 PMID: 9753033
  9. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
    Clin Cancer Res. 2005 Mar 1;11(5):1786-90 PMID: 15756000
  10. International staging system for multiple myeloma.
    J Clin Oncol. 2005 May 20;23(15):3412-20 PMID: 15809451
  11. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.
    Blood. 2005 Aug 1;106(3):812-7 PMID: 15855274
  12. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
    J Clin Oncol. 2005 Jul 20;23(21):4662-8 PMID: 16034042
  13. Multiple myeloma: diagnosis and treatment.
    Mayo Clin Proc. 2005 Oct;80(10):1371-82 PMID: 16212152
  14. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment.
    Mayo Clin Proc. 2006 May;81(5):693-703 PMID: 16706268
  15. International uniform response criteria for multiple myeloma.
    Leukemia. 2006 Sep;20(9):1467-73 PMID: 16855634
  16. Immunoglobulin free light chains and solitary plasmacytoma of bone.
    Blood. 2006 Sep 15;108(6):1979-83 PMID: 16741249
  17. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
    Blood. 2008 Jan 15;111(2):785-9 PMID: 17942755
  18. Clinically relevant end points and new drug approvals for myeloma.
    Leukemia. 2008 Feb;22(2):231-9 PMID: 17972944
  19. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.
    Leukemia. 2008 Oct;22(10):1933-7 PMID: 18596742
  20. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.
    Blood. 2003 Nov 15;102(10):3759-64 PMID: 12881316
  21. Solitary plasmacytoma of bone and extramedullary plasmacytoma.
    Hematol Oncol Clin North Am. 1999 Dec;13(6):1249-57 PMID: 10626148
  22. Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
    Blood. 2000 Sep 15;96(6):2037-44 PMID: 10979944
  23. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.
    Blood. 2001 Mar 15;97(6):1566-71 PMID: 11238092
  24. Hypodiploidy is a major prognostic factor in multiple myeloma.
    Blood. 2001 Oct 1;98(7):2229-38 PMID: 11568011
  25. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma.
    Br J Haematol. 2002 Sep;118(4):1041-7 PMID: 12199783
  26. Review of 1027 patients with newly diagnosed multiple myeloma.
    Mayo Clin Proc. 2003 Jan;78(1):21-33 PMID: 12528874
  27. POEMS syndrome: definitions and long-term outcome.
    Blood. 2003 Apr 1;101(7):2496-506 PMID: 12456500
  28. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Semin Oncol. 2003 Apr;30(2):110-5 PMID: 12720118
  29. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.
    Semin Oncol. 2003 Apr;30(2):169-71 PMID: 12720130
Article Info
Journal
Leukemia
Abbr.
Leukemia
ISSN
1476-5551
DOI
10.1038/leu.2008.291
Email
kyle.robert@mayo.edu
Published
2009-01-00
Epub
2008-00-30
Pages
3-9
Language
English
Region
England
NLM ID
8704895
PMCID
PMC2627786
Subset
IM
Grants
NCI NIH HHS · P01 CA062242-130011 · United States
NCI NIH HHS · P01 CA062242 · United States
NCI NIH HHS · R01 CA107476-05 · United States
NCI NIH HHS · R01 CA107476 · United States
NCI NIH HHS · CA107476 · United States
NCI NIH HHS · CA62242 · United States
Corrections
ErratumIn
-
External Links
PubMed source DOI: 10.1038/leu.2008.291 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2